Foresee Pharmaceuticals Co., Ltd. 6576

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the appointment of Brian J. Groch as Chief Commercial Officer, effective July 1, 2026. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with Haukeland University Hospital, Bergen, Norway.

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the successful completion of the Casppian Phase 3 clinical trial, with the Last Patient Last Visit (LPLV) now concluded. This milestone follows the previously reported positive topline results demonstrating that FP-001 42 mg (leuprolide mesylate), an investigational, sustained-release GnRH agonist administered every six months, met its primary efficacy endpoint in children with Central Precocious Puberty (CPP).